JAAQ secures £13 million Series A

By Published On: March 24, 2026Last Updated: March 24, 2026
JAAQ secures £13 million Series A

JAAQ has raised £13m in series A funding for its digital health and engagement platform, which embeds mental health content into user, patient and customer journeys.

Powered by an AI-native approach, JAAQ says its bespoke library of more than 10,000 clinically reviewed videos can be integrated into partners’ products or hosted as a bespoke JAAQ experience.

The company says its platform is designed for safety and enterprise use, combining clinically governed mental health engagement with behavioural pathways that aim to drive digital outcomes.

As part of the raise, Alex Packham, a serial entrepreneur and technology investor whose previous business was acquired by Adobe, has joined as chief executive.

Packham said: “We have a structural problem in mental health: demand is infinite, capacity is finite.

“The answer isn’t choosing between technology and therapists, it’s using technology to reach millions of people who will never see a therapist.

“Clinically governed mental health content, embedded inside the digital experiences people already use, is how we close that gap.

“But this isn’t just a mental health story, it’s a digital engagement story too.

“Organisations want their users to actually engage with what they build. JAAQ is the platform that makes both happen, safely and at scale.”

JAAQ is also investing in engineering infrastructure to help AI-native products and teams integrate its clinically governed content into tailored user journeys across clinical, enterprise and insurance settings. The company says clinical safety and human understanding sit at the core of its approach.

The investment will be used to accelerate enterprise partnerships, deepen clinical infrastructure and expand into US markets, while scaling deployment across enterprise, healthcare and insurance organisations globally.

Saurabh Johri, chief product and technology officer, brings more than 20 years of experience working at the intersection of AI/ML and healthcare, from research through to product development.

Johri said: “Having worked across healthcare for two decades, from research through to product, I’ve learned that what separates platforms that get adopted from those that don’t is trust: earned through clinical rigour, and through personalised experiences that reflect the individual not the population. Mental health is not one size that fits all, and the content and processes that govern what we deliver reflect that.”

He added: “What excites me about JAAQ is the content proposition itself, we’re developing a new modality that combines conversational AI with video, to give people a simple, tailored way to understand their health.

“Not another chatbot. Something that meets people where they are, in a format that feels native to how they already consume information, underpinned by clinical credibility at every layer.

He said: “The infrastructure we’re building is designed to make that experience scalable, safe, and deeply integrated into the digital environments where people already are.”

The funding round included investment from Meridian Health Ventures, Fuel Ventures, Bolt Angels and Guinness Ventures. Dr Pooja Sikka, partner at Meridian Health Ventures, has joined JAAQ’s board as part of the investment.

Sikka said: “JAAQ is solving a critical problem in mental health: not replacing care, but unlocking access to it.

“Their clinically governed approach and institutional integrations are exactly what the market needs. Their approach is unique.

“We believe JAAQ will become the infrastructure of mental health engagement for healthcare systems at a time when demand is overwhelming.”

Shiv Patel, partner at Fuel Ventures, said: “We’re delighted to be backing Alex again.

“What stood out to us is JAAQ’s ability to combine purpose with a commercially robust model. This is a platform designed for real-world adoption, scale and business impact, not just downloads.”

What is SmartNT? Inside the protocol improving first-trimester assessment for increased nuchal translucency
Why the UK must rethink prostate cancer screening